Orris

Write in detail about gene expression and gene mutations. Write in detail about DNA recombinant technology and its applications. Write in detail about gene therapy and RNA processing. Write in detail about MAPK signalling pathways in eukaryotic cells. Explain protein synthesis in detail.Explain the Ras–MAP kinase pathway and signal transduction through ion channels. these are the LAQs , so givde me exam oriented ans like topper and also add diagrams related to the tropics

Reading File
This is a large set of six major LAQs (Long Answer Questions) covering molecular biology and cell signaling — each one alone would normally run several pages in an exam answer with diagrams. Rather than compress all six into shallow answers, let me map out the full scope first.

Topic Breakdown

  1. Gene Expression and Gene Mutations — regulation of gene expression (prokaryotic/eukaryotic), types of mutations (point, frameshift, silent, missense, nonsense), causes and consequences, DNA repair
  2. Recombinant DNA Technology and Applications — restriction enzymes, vectors, cloning steps, PCR, applications in medicine/agriculture/industry
  3. Gene Therapy and RNA Processing — types of gene therapy (ex vivo/in vivo), vectors, examples (SCID, ADA deficiency); RNA processing (capping, splicing, polyadenylation, editing)
  4. MAPK Signalling Pathway in Eukaryotic Cells — ERK/JNK/p38 cascades, upstream activators, biological roles
  5. Protein Synthesis — transcription, translation (initiation, elongation, termination), post-translational modification
  6. Ras-MAP Kinase Pathway and Signal Transduction through Ion Channels — Ras activation cascade, ligand-gated/voltage-gated channels, second messengers

Brief Overview

These topics form the core of molecular biology/biochemistry exam papers: how genetic information is expressed and altered (Topics 1, 5), how we manipulate genes in the lab and clinic (Topics 2, 3), and how cells receive and transmit external signals (Topics 4, 6). Ras-MAPK (Topic 6) is actually a deeper dive into the same cascade as Topic 4, so they overlap significantly.
Given the depth needed for topper-level exam answers with proper diagrams, mechanisms, and clinical correlations, I can't do justice to all six in one response without making it superficial.
Which topic should I go deep on first?
Asking for Preferences

Which LAQ topic should I write in full exam-oriented detail first (with diagrams)?

This is a large set of six major LAQs (Long Answer Questions) covering molecular biology and cell signaling — each one alone would normally run several pages in an exam answer with diagrams. Rather than compress all six into shallow answers, let me map out the full scope first.

Topic Breakdown

  1. Gene Expression and Gene Mutations — regulation of gene expression (prokaryotic/eukaryotic), types of mutations (point, frameshift, silent, missense, nonsense), causes and consequences, DNA repair
  2. Recombinant DNA Technology and Applications — restriction enzymes, vectors, cloning steps, PCR, applications in medicine/agriculture/industry
  3. Gene Therapy and RNA Processing — types of gene therapy (ex vivo/in vivo), vectors, examples (SCID, ADA deficiency); RNA processing (capping, splicing, polyadenylation, editing)
  4. MAPK Signalling Pathway in Eukaryotic Cells — ERK/JNK/p38 cascades, upstream activators, biological roles
  5. Protein Synthesis — transcription, translation (initiation, elongation, termination), post-translational modification
  6. Ras-MAP Kinase Pathway and Signal Transduction through Ion Channels — Ras activation cascade, ligand-gated/voltage-gated channels, second messengers

Brief Overview

These topics form the core of molecular biology/biochemistry exam papers: how genetic information is expressed and altered (Topics 1, 5), how we manipulate genes in the lab and clinic (Topics 2, 3), and how cells receive and transmit external signals (Topics 4, 6). Ras-MAPK (Topic 6) is actually a deeper dive into the same cascade as Topic 4, so they overlap significantly.
Given the depth needed for topper-level exam answers with proper diagrams, mechanisms, and clinical correlations, I can't do justice to all six in one response without making it superficial.
Which topic should I go deep on first?

Quick answer

LAQ Answers — Molecular Biology & Cell Signalling (Exam-Oriented)

(Note: diagrams are described schematically in text since this answer is generated without image tools active. I recommend drawing labelled diagrams as indicated in the exam.)

1. Gene Expression and Gene Mutations

A. Gene Expression

Definition: Gene expression is the process by which information encoded in a gene is used to direct the synthesis of a functional gene product (protein or RNA).
Steps:
  1. Transcription — DNA → mRNA (in nucleus, by RNA polymerase)
  2. RNA processing — capping, splicing, polyadenylation (eukaryotes)
  3. Translation — mRNA → protein (on ribosomes)
  4. Post-translational modification — folding, glycosylation, phosphorylation
Regulation of Gene Expression:
Prokaryotic (Operon model — e.g., Lac operon):
  • Structural genes (lacZ, lacY, lacA) under control of a single promoter/operator
  • Negative control: Repressor protein (lacI) binds operator, blocks RNA polymerase, in absence of lactose
  • Induction: Allolactose binds repressor → repressor releases operator → transcription proceeds
  • Positive control: CAP-cAMP complex enhances promoter binding when glucose is low (catabolite repression)
Eukaryotic gene regulation (multiple levels):
LevelMechanism
Chromatin levelHistone acetylation/methylation, DNA methylation (epigenetics)
TranscriptionalPromoters, enhancers, silencers, transcription factors
Post-transcriptionalAlternative splicing, RNA editing, miRNA/siRNA silencing
TranslationalmRNA stability, initiation factor regulation
Post-translationalProtein modification, degradation (ubiquitin-proteasome)
Diagram to draw: Lac operon in "off" state (repressor bound to operator) vs "on" state (allolactose-repressor complex releasing operator, RNA polymerase transcribing structural genes).

B. Gene Mutations

Definition: A mutation is a permanent, heritable change in the nucleotide sequence of DNA.
Classification:
1. Based on size:
  • Point mutation — single base pair change
    • Substitution: one base replaced by another
      • Silent mutation (no change in amino acid, due to codon degeneracy)
      • Missense mutation (changes amino acid) — e.g., Sickle cell anemia (GAG→GTG, Glu→Val at position 6 of β-globin)
      • Nonsense mutation (creates premature stop codon) — e.g., some β-thalassemias
    • Frameshift mutation: insertion/deletion of bases not in multiples of 3, shifts reading frame downstream
2. Based on origin:
  • Spontaneous (replication errors, tautomeric shifts, depurination)
  • Induced (chemical mutagens, radiation, UV light)
3. Based on effect:
  • Loss of function
  • Gain of function
  • Dominant negative
  • Neutral/silent
Mutagens:
  • Physical: UV rays, X-rays, gamma rays
  • Chemical: Nitrous acid, alkylating agents, base analogs (5-bromouracil), intercalating agents (ethidium bromide)
  • Biological: Transposons, viruses
DNA Repair Mechanisms (clinically important):
Repair typeMechanismDefect disease
Base excision repair (BER)Removes single damaged base—
Nucleotide excision repair (NER)Removes damaged nucleotide stretch (UV damage)Xeroderma pigmentosum
Mismatch repair (MMR)Corrects replication errorsLynch syndrome (HNPCC)
Non-homologous end joining/Homologous recombinationDouble strand break repairBRCA1/2 mutations (breast/ovarian cancer)
Clinical correlation to mention for marks: Sickle cell disease (missense), Cystic fibrosis (ΔF508, deletion), Duchenne muscular dystrophy (frameshift/deletion), Beta-thalassemia (nonsense/splice site mutations).
Diagram to draw: Types of point mutations shown against a normal DNA/mRNA/protein sequence — silent, missense, nonsense, frameshift, side by side.

2. Recombinant DNA Technology and Its Applications

Definition: Technique of artificially combining DNA from two different sources (usually different species) to produce a recombinant molecule, which is then introduced into a host to express a desired product.

Steps involved (write as a flowchart for exam marks):

1. Isolation of DNA (gene of interest) — from donor organism
2. Restriction digestion
  • Restriction endonucleases (e.g., EcoRI, BamHI, HindIII) cut DNA at specific palindromic sequences, producing "sticky ends"
3. Selection of a vector
  • Plasmids (pBR322, pUC), bacteriophages (lambda), cosmids, Ti plasmid (in plants), viral vectors (adenovirus, retrovirus, AAV — for eukaryotic/gene therapy use)
  • Vector must have: origin of replication, selectable marker (antibiotic resistance), multiple cloning site
4. Ligation
  • DNA ligase joins the foreign DNA fragment (insert) with the cut vector, forming recombinant DNA
5. Transformation/Transfection
  • Recombinant DNA introduced into host cell (bacteria — E. coli; or eukaryotic cells) via:
    • Heat shock/CaCl₂ method
    • Electroporation
    • Microinjection
    • Gene gun (biolistic method)
    • Viral vector-mediated transfer
6. Selection of transformants
  • Using antibiotic resistance markers or blue-white screening (lacZ system)
7. Screening for the gene of interest
  • Colony hybridization, PCR-based screening
8. Expression/Cloning
  • Amplification of the gene, or expression of protein product

Polymerase Chain Reaction (PCR) — important allied technique

  • In vitro amplification of DNA using:
    • Template DNA
    • Primers (forward/reverse)
    • Taq DNA polymerase (thermostable)
    • dNTPs
  • Steps: Denaturation (94-96°C) → Annealing (50-65°C) → Extension (72°C) — repeated cycles (exponential amplification)
Diagram to draw: Complete rDNA technology flowchart — isolate gene → cut with restriction enzyme → cut vector with same enzyme → ligate with DNA ligase → transform into host bacterium → select on antibiotic plate → clone/express.

Applications of Recombinant DNA Technology

A. Medical:
  • Recombinant insulin (Humulin) — first rDNA product, produced in E. coli
  • Human growth hormone (Somatotropin) for dwarfism
  • Hepatitis B vaccine — recombinant surface antigen
  • Factor VIII/IX for hemophilia
  • Erythropoietin for anemia
  • Monoclonal antibodies (trastuzumab, rituximab)
  • Gene therapy vectors
  • Diagnostic tools: DNA probes, PCR-based diagnosis (e.g., HIV, TB, COVID-19 RT-PCR)
B. Agricultural:
  • Bt cotton/Bt brinjal (pest resistance via Cry genes from Bacillus thuringiensis)
  • Golden rice (Vitamin A enriched, beta-carotene pathway genes)
  • Herbicide-resistant crops (Roundup Ready soybean)
  • Flavr Savr tomato (delayed ripening)
C. Industrial:
  • Enzyme production (proteases, amylases for detergents)
  • Biofuel production
D. Forensic:
  • DNA fingerprinting (RFLP, STR analysis) for paternity testing, criminal identification
E. Research:
  • Gene knockout/knock-in studies
  • Transgenic animal models (e.g., transgenic mice)
  • CRISPR-Cas9 genome editing (modern extension of rDNA technology)

3. Gene Therapy and RNA Processing

A. Gene Therapy

Definition: Introduction, removal, or alteration of genetic material within a patient's cells to treat a disease.
Types:
1. Based on target cell:
  • Germline gene therapy — modifies germ cells (sperm/egg); changes heritable; ethically controversial, not used clinically in humans
  • Somatic gene therapy — modifies somatic cells; not heritable; clinically approved approach
2. Based on method:
  • Ex vivo gene therapy: Cells removed from patient → gene inserted in vitro → modified cells reintroduced
    • Example: ADA-SCID (Adenosine Deaminase deficiency - Severe Combined Immunodeficiency) — first successful gene therapy (1990, by W. French Anderson): lymphocytes withdrawn, functional ADA gene introduced via retroviral vector, reinfused
  • In vivo gene therapy: Vector carrying therapeutic gene directly administered into patient's body
    • Example: Luxturna (RPE65 gene, for inherited retinal dystrophy), Zolgensma (SMN1 gene for spinal muscular atrophy)
Vectors used in gene therapy:
VectorFeature
RetrovirusIntegrates into host genome; used for dividing cells
AdenovirusNon-integrating, strong immune response
Adeno-associated virus (AAV)Low immunogenicity, widely used now
LentivirusCan infect non-dividing cells
Liposomes/Naked DNANon-viral, safer but less efficient
Approaches:
  • Gene augmentation (adding a normal copy of gene)
  • Gene silencing (using antisense/siRNA to block defective gene)
  • Gene editing (CRISPR-Cas9, to correct the mutation directly)
  • Oncolytic virus therapy (for cancers)
Diagram to draw: Ex vivo vs in vivo gene therapy comparison chart with retroviral vector transducing target cell.
Challenges: Immune response, insertional mutagenesis (risk of oncogene activation, as seen in some X-SCID trials), transient expression, high cost, delivery efficiency.

B. RNA Processing (Post-transcriptional modification of pre-mRNA)

Occurs in the nucleus after transcription by RNA Pol II, converting primary transcript (pre-mRNA/hnRNA) into mature mRNA.
Three major steps:
1. 5' Capping
  • Addition of 7-methylguanosine cap to the 5' end
  • Function: Protects mRNA from degradation (5'→3' exonucleases), assists ribosome binding for translation initiation
2. Splicing
  • Removal of introns (non-coding intervening sequences) and joining of exons (coding sequences)
  • Carried out by the spliceosome — a complex of snRNPs (U1, U2, U4, U5, U6 small nuclear RNAs + proteins)
  • Mechanism: recognizes GU (5' splice site) and AG (3' splice site) consensus sequences, forms a lariat structure, cuts and ligates exons
  • Alternative splicing: different combinations of exons joined → multiple protein isoforms from a single gene (major source of proteome diversity)
3. 3' Polyadenylation
  • Cleavage downstream of AAUAAA signal sequence
  • Addition of ~200 adenine residues (poly-A tail) by poly-A polymerase
  • Function: mRNA stability, export from nucleus, translation efficiency
Other RNA processing events:
  • RNA editing — post-transcriptional alteration of RNA sequence (e.g., ApoB mRNA editing, ADAR enzymes converting A→I)
  • RNA interference (RNAi) — siRNA/miRNA-mediated silencing of gene expression
Diagram to draw: Pre-mRNA with exons/introns → capping at 5' end → spliceosome removing introns (lariat intermediate) → poly-A tail addition at 3' end → mature mRNA exiting nuclear pore.

4. MAPK Signalling Pathway in Eukaryotic Cells

MAPK (Mitogen-Activated Protein Kinase) pathway is a conserved three-tiered kinase cascade that transduces extracellular signals (growth factors, cytokines, stress) into intracellular responses (proliferation, differentiation, apoptosis).

General Architecture (three-tier kinase cascade):

Extracellular signal (growth factor)
        ↓
Receptor (RTK) activation
        ↓
MAPKKK (MAP kinase kinase kinase) — e.g., Raf
        ↓ (phosphorylates)
MAPKK (MAP kinase kinase) — e.g., MEK
        ↓ (phosphorylates on Thr and Tyr)
MAPK (MAP kinase) — e.g., ERK
        ↓
Nuclear translocation → Transcription factor activation → Gene expression

Major MAPK sub-families:

PathwayActivated byKey kinasesMain outcome
ERK1/2 (classical)Growth factors (EGF, PDGF) via RTK-RasRaf → MEK1/2 → ERK1/2Cell proliferation, differentiation
JNK (SAPK)Stress, UV, cytokines (TNF, IL-1)MEKK → MKK4/7 → JNKApoptosis, inflammation
p38 MAPKOsmotic stress, inflammatory cytokinesMEKK → MKK3/6 → p38Inflammation, apoptosis, stress response

Mechanism of activation (ERK pathway as prototype):

  1. Growth factor binds Receptor Tyrosine Kinase (RTK) → receptor dimerization and autophosphorylation
  2. Adaptor protein Grb2 binds phosphotyrosine residues
  3. Grb2 recruits SOS (guanine nucleotide exchange factor)
  4. SOS activates Ras (GDP → GTP exchange)
  5. Ras-GTP activates Raf (MAPKKK)
  6. Raf phosphorylates and activates MEK (MAPKK)
  7. MEK phosphorylates ERK (MAPK) on both threonine and tyrosine residues
  8. Activated ERK translocates to nucleus, phosphorylates transcription factors (Elk-1, c-Fos, c-Myc)
  9. Gene transcription → cell cycle progression, proliferation
Termination/Regulation: MAPK phosphatases (MKPs/DUSPs) dephosphorylate and inactivate MAPKs; negative feedback loops.
Clinical relevance:
  • Mutated Ras (oncogene, e.g., KRAS in pancreatic/colorectal cancer) or BRAF (V600E mutation in melanoma) causes constitutive MAPK activation → uncontrolled proliferation → cancer
  • Targeted drugs: Vemurafenib (BRAF inhibitor), Trametinib (MEK inhibitor)
Diagram to draw: Three-tiered cascade box diagram: RTK at membrane → Grb2-SOS → Ras → Raf (MAPKKK) → MEK (MAPKK) → ERK (MAPK) → nucleus with transcription factor activation, showing branching into ERK/JNK/p38 arms.

5. Protein Synthesis (Translation) — Detailed

Protein synthesis has two major phases: Transcription (DNA→mRNA, covered above) and Translation (mRNA→protein). Here is translation in detail as typically asked:

Requirements:

  • mRNA (template)
  • Ribosomes (70S in prokaryotes: 30S+50S; 80S in eukaryotes: 40S+60S)
  • tRNA (adaptor molecules, charged with amino acids)
  • Aminoacyl-tRNA synthetases (charge tRNA with correct amino acid — ATP dependent)
  • Initiation, elongation, release factors
  • GTP, Mg²⁺

Steps of Translation:

1. Activation of amino acid
  • Amino acid + ATP + tRNA → aminoacyl-tRNA (charged tRNA) + AMP + PPi (catalyzed by aminoacyl-tRNA synthetase — high specificity/proofreading step)
2. Initiation
  • Small ribosomal subunit binds mRNA at 5' cap (eukaryotes) or Shine-Dalgarno sequence (prokaryotes)
  • Initiator tRNA (Met-tRNA in eukaryotes, fMet-tRNA in prokaryotes) pairs with start codon (AUG)
  • Initiation factors (eIFs in eukaryotes, IFs in prokaryotes) mediate assembly
  • Large ribosomal subunit joins → forms complete initiation complex with initiator tRNA in P site
3. Elongation (cyclical, repeated for each codon)
  • Codon recognition: Aminoacyl-tRNA (matching next codon) enters A site, assisted by elongation factor (EF-Tu/eEF1, GTP-dependent)
  • Peptide bond formation: Peptidyl transferase (a ribozyme activity of large rRNA) catalyzes bond between amino acid in A site and growing peptide chain in P site
  • Translocation: Ribosome moves one codon (3 nucleotides) along mRNA (5'→3'), catalyzed by EF-G/eEF2 (GTP-dependent); tRNA shifts from A→P→E sites, empty tRNA exits from E site
4. Termination
  • Stop codon (UAA, UAG, UGA) enters A site — no corresponding tRNA
  • Release factors (RF1/RF2/RF3 in prokaryotes; eRF1/eRF3 in eukaryotes) bind
  • Peptidyl transferase hydrolyzes bond between polypeptide and tRNA → releases polypeptide
  • Ribosomal subunits dissociate
5. Post-translational modifications
  • Folding (chaperones — Hsp70, chaperonins)
  • Cleavage of signal peptides
  • Glycosylation, phosphorylation, disulfide bond formation, ubiquitination
  • Targeting to organelles (via signal sequences, e.g., ER, mitochondria, nucleus)

Key features to mention for marks:

  • Genetic code is triplet, degenerate, non-overlapping, nearly universal, unambiguous
  • Polysome/Polyribosome: multiple ribosomes translating same mRNA simultaneously — increases efficiency
  • Wobble hypothesis: explains degeneracy — third codon base pairing is flexible
Diagram to draw: Ribosome with A, P, E sites labeled, mRNA threading through, tRNA entering A site with amino acid, peptide bond formation, and translocation arrow — label small/large subunits, growing polypeptide chain.

6. Ras-MAP Kinase Pathway and Signal Transduction through Ion Channels

A. Ras-MAP Kinase Pathway (detailed mechanism — expands on Topic 4)

Ras is a small monomeric G-protein (21 kDa) that acts as a molecular switch, cycling between inactive (Ras-GDP) and active (Ras-GTP) states.
Step-by-step signal transduction:
  1. Ligand binding: Growth factor (e.g., EGF) binds extracellular domain of Receptor Tyrosine Kinase (RTK)
  2. Receptor dimerization and trans-autophosphorylation of intracellular tyrosine residues
  3. Adaptor recruitment: Grb2 (via SH2 domain) binds phosphotyrosines
  4. GEF recruitment: Grb2 (via SH3 domain) recruits SOS (Son of Sevenless — a Guanine nucleotide Exchange Factor)
  5. Ras activation: SOS catalyzes exchange of GDP for GTP on Ras → Ras-GTP (active form)
  6. Ras-GTP activates Raf (serine/threonine kinase, MAPKKK) by recruiting it to the membrane
  7. Raf phosphorylates MEK (MAPKK)
  8. MEK phosphorylates ERK (MAPK) on Thr and Tyr residues (dual phosphorylation)
  9. ERK dimerizes, translocates to nucleus
  10. Phosphorylates transcription factors (Elk-1, c-Fos, c-Jun, c-Myc) → activates immediate early genes → cell proliferation, differentiation, survival
Inactivation: GAP (GTPase Activating Protein) enhances intrinsic GTPase activity of Ras → hydrolyzes GTP to GDP → Ras returns to inactive state (negative regulation)
Clinical significance:
  • Oncogenic RAS mutations (point mutations at codons 12, 13, 61) impair GAP-mediated GTP hydrolysis → Ras locked in active GTP-bound state → constitutive proliferative signaling → found in ~30% of human cancers (pancreatic, colorectal, lung)
  • This pathway is a major target for anticancer drug development
Diagram to draw: Membrane receptor → Grb2-SOS complex → Ras (GDP↔GTP cycle with GEF/GAP) → Raf → MEK → ERK → nucleus, with a side inset showing normal GTPase cycle vs oncogenic Ras stuck in GTP-bound state.

B. Signal Transduction through Ion Channels

Ion channel-linked receptors (ionotropic receptors) provide the fastest mode of signal transduction (milliseconds), primarily in excitable tissue (neurons, muscle).
Types of ion channels involved in signalling:
1. Ligand-gated ion channels (Ionotropic receptors)
  • Channel opens directly upon neurotransmitter binding (no second messenger needed)
  • Examples:
    • Nicotinic acetylcholine receptor — cation channel (Na⁺/K⁺), opens on ACh binding → depolarization → muscle contraction
    • GABA-A receptor — Cl⁻ channel, opens on GABA binding → hyperpolarization → inhibitory neurotransmission
    • Glutamate receptors (NMDA, AMPA) — cation channels, excitatory transmission
2. Voltage-gated ion channels
  • Open/close in response to changes in membrane potential
  • Examples: Voltage-gated Na⁺ channels (action potential generation/upstroke), voltage-gated K⁺ channels (repolarization), voltage-gated Ca²⁺ channels (neurotransmitter release, muscle contraction, second messenger generation)
3. Second messenger-gated (G-protein coupled) ion channels
  • Indirect gating: GPCR activation → G-protein → second messenger (cAMP, IP3, DAG) → modulates channel
  • Example: cGMP-gated channels in retinal rod cells (phototransduction); cardiac muscarinic K⁺ channels via Gβγ subunits
Mechanism (example — Nicotinic ACh receptor at neuromuscular junction):
  1. Action potential reaches presynaptic terminal
  2. Voltage-gated Ca²⁺ channels open → Ca²⁺ influx
  3. Ca²⁺ triggers synaptic vesicle fusion → ACh release into synaptic cleft
  4. ACh binds nicotinic receptor (ligand-gated Na⁺/K⁺ channel) on postsynaptic membrane
  5. Conformational change opens channel → Na⁺ influx (net) → depolarization (End Plate Potential)
  6. If threshold reached → voltage-gated Na⁺ channels open → action potential propagates → muscle contraction
Key features distinguishing ion channel signalling from other pathways:
  • Extremely rapid response (milliseconds vs seconds-minutes for GPCR/RTK pathways)
  • Directly converts chemical signal into electrical signal
  • No amplification via enzymatic cascade (unlike GPCR/second messenger systems) — a direct structural change
Diagram to draw: Neuromuscular junction — presynaptic terminal with voltage-gated Ca²⁺ channels, synaptic vesicles releasing ACh, postsynaptic membrane with nicotinic ligand-gated Na⁺/K⁺ channel opening, and ion flow arrows.

Exam tip summary

For each of these LAQs, structure your answer as: Definition → Classification/Types → Mechanism (stepwise, use flowcharts) → Labelled diagram → Clinical/biotechnological significance → Conclusion. This structure consistently scores full marks because examiners look for definition, mechanism with sequence, and application/relevance.
Searching Images

gene mutation types point mutation frameshift diagram

Searching Images

recombinant DNA technology cloning steps diagram plasmid vector

Searching Images

RNA processing pre-mRNA splicing capping polyadenylation diagram

Searching Images

MAPK signaling pathway cascade diagram Ras Raf MEK ERK

A pathophysiology diagram illustrating the canonical MAPK/ERK signaling pathway and its exploitation by viral pathogens. The diagram shows the cell membrane with various receptors, including Receptor Tyrosine Kinases (RTK) and G-protein coupled receptors (GPCR), responding to growth factors, cytokines, chemokines, and viruses. The intracellular signaling cascade initiates with Grb2 and SOS facilitating the transition of RAS-GDP to RAS-GTP. The signal proceeds through a sequential phosphorylation relay of RAF, MEK, and ERK. Activated ERK translocates from the cytoplasm to the nucleus, where it activates transcription factors Fos and ELK to influence gene expression. The diagram highlights points of viral interference: SARS-CoV-2 entry via ACE2, influenza replication utilizing RSK1, and HIV replication involving Gag MA, all linked to downstream ERK components. Key pharmacological inhibitors for potential therapeutic repurposing are noted, including Vemurafenib/Dabrafenib (RAF), Trametinib/Cobimetinib (MEK), and ONC201/Ulixertinib (ERK), alongside RAS inhibitors like ARS-853.

A pathophysiology diagram illustrating the canonical MAPK/ERK signaling pathway and its exploitation by viral pathogens. The diagram shows the cell membrane with various receptors, including Receptor Tyrosine Kinases (RTK) and G-protein coupled receptors (GPCR), responding to growth factors, cytokines, chemokines, and viruses. The intracellular signaling cascade initiates with Grb2 and SOS facilitating the transition of RAS-GDP to RAS-GTP. The signal proceeds through a sequential phosphorylation relay of RAF, MEK, and ERK. Activated ERK translocates from the cytoplasm to the nucleus, where it activates transcription factors Fos and ELK to influence gene expression. The diagram highlights points of viral interference: SARS-CoV-2 entry via ACE2, influenza replication utilizing RSK1, and HIV replication involving Gag MA, all linked to downstream ERK components. Key pharmacological inhibitors for potential therapeutic repurposing are noted, including Vemurafenib/Dabrafenib (RAF), Trametinib/Cobimetinib (MEK), and ONC201/Ulixertinib (ERK), alongside RAS inhibitors like ARS-853.

This pathophysiology diagram illustrates the complex signaling network involving SOX2 in bladder cancer cells, highlighting its role in tumor proliferation and chemoresistance. The diagram is divided into four main regulatory pathways: (A) The MAPK/ERK pathway, showing the RAS-RAF-MEK-ERK cascade where active RAS-GTP leads to ERK phosphorylation (pERK) and subsequent SOX2 activation, regulated by RASAL2. (B) The MAPK/JNK pathway, where ChlA-F triggers JNK and c-Jun phosphorylation, modulating SOX2 via miR-200c. (C) The SOX2-IGF2-AKT axis, demonstrating a positive feedback loop where SOX2 promotes IGF2 expression (inhibiting IGFBP1), which then activates AKT via phosphorylation (pAKT). (D) The COX2/PGE2 and YAP1 pathways, showing YAP1 directly activating SOX2 and COX2, while the COX2-PGE2 axis inhibits let-7, a microRNA that typically represses SOX2. Centrally, SOX2 acts as a master transcription factor that drives the transformation of bladder cancer cells into phenotypes characterized by rapid proliferation and enhanced chemoresistance.

This pathophysiology diagram illustrates the complex signaling network involving SOX2 in bladder cancer cells, highlighting its role in tumor proliferation and chemoresistance. The diagram is divided into four main regulatory pathways: (A) The MAPK/ERK pathway, showing the RAS-RAF-MEK-ERK cascade where active RAS-GTP leads to ERK phosphorylation (pERK) and subsequent SOX2 activation, regulated by RASAL2. (B) The MAPK/JNK pathway, where ChlA-F triggers JNK and c-Jun phosphorylation, modulating SOX2 via miR-200c. (C) The SOX2-IGF2-AKT axis, demonstrating a positive feedback loop where SOX2 promotes IGF2 expression (inhibiting IGFBP1), which then activates AKT via phosphorylation (pAKT). (D) The COX2/PGE2 and YAP1 pathways, showing YAP1 directly activating SOX2 and COX2, while the COX2-PGE2 axis inhibits let-7, a microRNA that typically represses SOX2. Centrally, SOX2 acts as a master transcription factor that drives the transformation of bladder cancer cells into phenotypes characterized by rapid proliferation and enhanced chemoresistance.

A pathophysiology diagram illustrating the ErbB/HER2 signaling network, organized into three functional sections: input, signal processing, and output. (a) The input part shows extracellular ligands binding to transmembrane ErbB receptors (EGFR, HER2, HER3, and HER4), highlighting the role of HER2 heterodimers. (b) The signal processing part depicts three vertical intracellular signaling cascades: the PI3K/AKT/mTOR pathway (green), the JAK/STAT3 pathway (blue), and the RAS/RAF/MEK/ERK (MAPK) pathway (yellow). Each cascade follows a downward flow of activation. (c) The output part shows these pathways converging on the cell nucleus, represented by a DNA double helix. This section indicates downstream cellular effects including cell division, migration, differentiation, and apoptosis. This schematic provides a clinical overview of how HER2 overexpression drives tumorigenic processes and drug resistance mechanisms in cancers such as invasive breast cancer.

A pathophysiology diagram illustrating the ErbB/HER2 signaling network, organized into three functional sections: input, signal processing, and output. (a) The input part shows extracellular ligands binding to transmembrane ErbB receptors (EGFR, HER2, HER3, and HER4), highlighting the role of HER2 heterodimers. (b) The signal processing part depicts three vertical intracellular signaling cascades: the PI3K/AKT/mTOR pathway (green), the JAK/STAT3 pathway (blue), and the RAS/RAF/MEK/ERK (MAPK) pathway (yellow). Each cascade follows a downward flow of activation. (c) The output part shows these pathways converging on the cell nucleus, represented by a DNA double helix. This section indicates downstream cellular effects including cell division, migration, differentiation, and apoptosis. This schematic provides a clinical overview of how HER2 overexpression drives tumorigenic processes and drug resistance mechanisms in cancers such as invasive breast cancer.

Searching Images

protein synthesis translation ribosome mRNA diagram initiation elongation termination

Searching Images

ion channel signal transduction ligand gated voltage gated diagram

Searching Images

gene therapy vector viral delivery diagram

This medical schematic illustrates a non-viral transposon-mediated gene therapy system, detailing the mechanisms of delivery, excision, and chromosomal integration. The diagram identifies two primary vector configurations: 'trans' delivery, involving two separate plasmids (one for the therapeutic gene of interest [GOI] and another for the transposase enzyme), and 'cis' delivery, where both components are housed on a single plasmid. Key molecular components include the GOI (green arrow), an upstream promoter (orange box), and flanking Inverted Terminal Repeats (ITRs, red circles). The educational focus highlights the three-step 'cut and paste' mechanism: (1) Nonviral delivery of the DNA vector into the target cell nucleus; (2) Excision of the transposon cassette by the transposase enzyme (blue) at the ITR recognition sites; and (3) Site-specific chromosomal integration into the host's genomic DNA, specifically targeting TTAA-rich sites. This process demonstrates a method for stable transgene insertion in human regenerative medicine and oncology applications, emphasizing a bi-component DNA vector system as an alternative to viral-mediated delivery.

This medical schematic illustrates a non-viral transposon-mediated gene therapy system, detailing the mechanisms of delivery, excision, and chromosomal integration. The diagram identifies two primary vector configurations: 'trans' delivery, involving two separate plasmids (one for the therapeutic gene of interest [GOI] and another for the transposase enzyme), and 'cis' delivery, where both components are housed on a single plasmid. Key molecular components include the GOI (green arrow), an upstream promoter (orange box), and flanking Inverted Terminal Repeats (ITRs, red circles). The educational focus highlights the three-step 'cut and paste' mechanism: (1) Nonviral delivery of the DNA vector into the target cell nucleus; (2) Excision of the transposon cassette by the transposase enzyme (blue) at the ITR recognition sites; and (3) Site-specific chromosomal integration into the host's genomic DNA, specifically targeting TTAA-rich sites. This process demonstrates a method for stable transgene insertion in human regenerative medicine and oncology applications, emphasizing a bi-component DNA vector system as an alternative to viral-mediated delivery.

This pathophysiology diagram illustrates the process of genetic engineering using the Type II CRISPR-Cas9 system. The top section displays a linear CRISPR construct containing, from left to right: a Promoter, CRISPR RNA and TRACR RNA (collectively labeled as Guide RNA), a second Promoter, the Cas9 nuclease gene, a Nuclear Localization Signal (NLS), and an Ampicillin Resistance (AmpR) marker. The diagram follows the workflow of inserting this construct into a viral vector, which is depicted as a spherical particle with surface proteins. The central section shows the transduction phase, where the viral vector infects a target cell to deliver the genetic material. The final section demonstrates the intracellular outcome: transcription and translation of the construct followed by the localized action of the CRISPR-Cas9 complex on the host genome. A specific interaction is highlighted where the complex identifies a Protospacer Adjacent Motif (PAM) site to facilitate precise DNA cleavage. This educational resource is designed to teach mechanisms of gene therapy, viral delivery systems, and precision molecular biology.

This pathophysiology diagram illustrates the process of genetic engineering using the Type II CRISPR-Cas9 system. The top section displays a linear CRISPR construct containing, from left to right: a Promoter, CRISPR RNA and TRACR RNA (collectively labeled as Guide RNA), a second Promoter, the Cas9 nuclease gene, a Nuclear Localization Signal (NLS), and an Ampicillin Resistance (AmpR) marker. The diagram follows the workflow of inserting this construct into a viral vector, which is depicted as a spherical particle with surface proteins. The central section shows the transduction phase, where the viral vector infects a target cell to deliver the genetic material. The final section demonstrates the intracellular outcome: transcription and translation of the construct followed by the localized action of the CRISPR-Cas9 complex on the host genome. A specific interaction is highlighted where the complex identifies a Protospacer Adjacent Motif (PAM) site to facilitate precise DNA cleavage. This educational resource is designed to teach mechanisms of gene therapy, viral delivery systems, and precision molecular biology.

This medical schematic illustrates two clinical pathways for gene therapy application during ex situ heart perfusion (ESHP). Pathway A depicts autotransplantation for genetic heart disease. It shows a sequence where a diseased heart is removed for ESHP treatment, during which the patient is supported by a cardiopulmonary bypass (CPB) circuit. The ESHP phase highlights the use of viral vectors (represented by icosahedral icons) for targeted gene editing before the treated organ is autotransplanted back into the same patient. Pathway B illustrates biological modification for orthotopic heart transplantation. A healthy donor heart undergoes ESHP for immunomodulation or physiological enhancement—again using viral vector delivery—prior to transplantation into a recipient. Both pathways utilize a perfusion circuit consisting of a pump and an oxygenator to maintain organ viability ex situ. This diagram emphasizes the clinical potential of ESHP as a controlled environment for localized cardiovascular gene therapy and organ optimization in transplant medicine.

This medical schematic illustrates two clinical pathways for gene therapy application during ex situ heart perfusion (ESHP). Pathway A depicts autotransplantation for genetic heart disease. It shows a sequence where a diseased heart is removed for ESHP treatment, during which the patient is supported by a cardiopulmonary bypass (CPB) circuit. The ESHP phase highlights the use of viral vectors (represented by icosahedral icons) for targeted gene editing before the treated organ is autotransplanted back into the same patient. Pathway B illustrates biological modification for orthotopic heart transplantation. A healthy donor heart undergoes ESHP for immunomodulation or physiological enhancement—again using viral vector delivery—prior to transplantation into a recipient. Both pathways utilize a perfusion circuit consisting of a pump and an oxygenator to maintain organ viability ex situ. This diagram emphasizes the clinical potential of ESHP as a controlled environment for localized cardiovascular gene therapy and organ optimization in transplant medicine.

Searching Images

DNA replication transcription translation central dogma diagram

Searching Images

restriction enzyme plasmid cloning vector bacteria

Searching Images

ribosome mRNA tRNA translation elongation cycle

Generating Image

A labeled scientific diagram showing types of gene mutations: silent, missense, nonsense, and frameshift mutations, comparing normal DNA/mRNA/protein sequence to mutated sequences

Generating Image

A labeled diagram showing steps of recombinant DNA technology: isolation of gene of interest, cutting with restriction enzyme, insertion into plasmid vector with ligase, transformation into host bacterial cell, and cloning

Generating Image

A labeled diagram of eukaryotic RNA processing showing pre-mRNA with introns and exons, 5' capping, splicing by spliceosome removing introns, and 3' polyadenylation to form mature mRNA

Generating Image

A labeled diagram of protein synthesis translation showing ribosome moving along mRNA with tRNA bringing amino acids, initiation, elongation with growing polypeptide chain, and termination at stop codon

Generating Image

A labeled diagram of signal transduction through ion channels in a cell membrane, showing a ligand-gated ion channel opening upon neurotransmitter binding and a voltage-gated ion channel opening upon membrane depolarization, with ion flow across the membrane

This is a large set of six major LAQs (Long Answer Questions) covering molecular biology and cell signaling — each one alone would normally run several pages in an exam answer with diagrams. Rather than compress all six into shallow answers, let me map out the full scope first.

Topic Breakdown

  1. Gene Expression and Gene Mutations — regulation of gene expression (prokaryotic/eukaryotic), types of mutations (point, frameshift, silent, missense, nonsense), causes and consequences, DNA repair
  2. Recombinant DNA Technology and Applications — restriction enzymes, vectors, cloning steps, PCR, applications in medicine/agriculture/industry
  3. Gene Therapy and RNA Processing — types of gene therapy (ex vivo/in vivo), vectors, examples (SCID, ADA deficiency); RNA processing (capping, splicing, polyadenylation, editing)
  4. MAPK Signalling Pathway in Eukaryotic Cells — ERK/JNK/p38 cascades, upstream activators, biological roles
  5. Protein Synthesis — transcription, translation (initiation, elongation, termination), post-translational modification
  6. Ras-MAP Kinase Pathway and Signal Transduction through Ion Channels — Ras activation cascade, ligand-gated/voltage-gated channels, second messengers

Brief Overview

These topics form the core of molecular biology/biochemistry exam papers: how genetic information is expressed and altered (Topics 1, 5), how we manipulate genes in the lab and clinic (Topics 2, 3), and how cells receive and transmit external signals (Topics 4, 6). Ras-MAPK (Topic 6) is actually a deeper dive into the same cascade as Topic 4, so they overlap significantly.
Given the depth needed for topper-level exam answers with proper diagrams, mechanisms, and clinical correlations, I can't do justice to all six in one response without making it superficial.
Which topic should I go deep on first?# LAQ Answers — Molecular Biology & Cell Signalling (Exam-Oriented)
(Note: diagrams are described schematically in text since this answer is generated without image tools active. I recommend drawing labelled diagrams as indicated in the exam.)

1. Gene Expression and Gene Mutations

A. Gene Expression

Definition: Gene expression is the process by which information encoded in a gene is used to direct the synthesis of a functional gene product (protein or RNA).
Steps:
  1. Transcription — DNA → mRNA (in nucleus, by RNA polymerase)
  2. RNA processing — capping, splicing, polyadenylation (eukaryotes)
  3. Translation — mRNA → protein (on ribosomes)
  4. Post-translational modification — folding, glycosylation, phosphorylation
Regulation of Gene Expression:
Prokaryotic (Operon model — e.g., Lac operon):
  • Structural genes (lacZ, lacY, lacA) under control of a single promoter/operator
  • Negative control: Repressor protein (lacI) binds operator, blocks RNA polymerase, in absence of lactose
  • Induction: Allolactose binds repressor → repressor releases operator → transcription proceeds
  • Positive control: CAP-cAMP complex enhances promoter binding when glucose is low (catabolite repression)
Eukaryotic gene regulation (multiple levels):
LevelMechanism
Chromatin levelHistone acetylation/methylation, DNA methylation (epigenetics)
TranscriptionalPromoters, enhancers, silencers, transcription factors
Post-transcriptionalAlternative splicing, RNA editing, miRNA/siRNA silencing
TranslationalmRNA stability, initiation factor regulation
Post-translationalProtein modification, degradation (ubiquitin-proteasome)
Diagram to draw: Lac operon in "off" state (repressor bound to operator) vs "on" state (allolactose-repressor complex releasing operator, RNA polymerase transcribing structural genes).

B. Gene Mutations

Definition: A mutation is a permanent, heritable change in the nucleotide sequence of DNA.
Classification:
1. Based on size:
  • Point mutation — single base pair change
    • Substitution: one base replaced by another
      • Silent mutation (no change in amino acid, due to codon degeneracy)
      • Missense mutation (changes amino acid) — e.g., Sickle cell anemia (GAG→GTG, Glu→Val at position 6 of β-globin)
      • Nonsense mutation (creates premature stop codon) — e.g., some β-thalassemias
    • Frameshift mutation: insertion/deletion of bases not in multiples of 3, shifts reading frame downstream
2. Based on origin:
  • Spontaneous (replication errors, tautomeric shifts, depurination)
  • Induced (chemical mutagens, radiation, UV light)
3. Based on effect:
  • Loss of function
  • Gain of function
  • Dominant negative
  • Neutral/silent
Mutagens:
  • Physical: UV rays, X-rays, gamma rays
  • Chemical: Nitrous acid, alkylating agents, base analogs (5-bromouracil), intercalating agents (ethidium bromide)
  • Biological: Transposons, viruses
DNA Repair Mechanisms (clinically important):
Repair typeMechanismDefect disease
Base excision repair (BER)Removes single damaged base—
Nucleotide excision repair (NER)Removes damaged nucleotide stretch (UV damage)Xeroderma pigmentosum
Mismatch repair (MMR)Corrects replication errorsLynch syndrome (HNPCC)
Non-homologous end joining/Homologous recombinationDouble strand break repairBRCA1/2 mutations (breast/ovarian cancer)
Clinical correlation to mention for marks: Sickle cell disease (missense), Cystic fibrosis (ΔF508, deletion), Duchenne muscular dystrophy (frameshift/deletion), Beta-thalassemia (nonsense/splice site mutations).
Diagram to draw: Types of point mutations shown against a normal DNA/mRNA/protein sequence — silent, missense, nonsense, frameshift, side by side.

2. Recombinant DNA Technology and Its Applications

Definition: Technique of artificially combining DNA from two different sources (usually different species) to produce a recombinant molecule, which is then introduced into a host to express a desired product.

Steps involved (write as a flowchart for exam marks):

1. Isolation of DNA (gene of interest) — from donor organism
2. Restriction digestion
  • Restriction endonucleases (e.g., EcoRI, BamHI, HindIII) cut DNA at specific palindromic sequences, producing "sticky ends"
3. Selection of a vector
  • Plasmids (pBR322, pUC), bacteriophages (lambda), cosmids, Ti plasmid (in plants), viral vectors (adenovirus, retrovirus, AAV — for eukaryotic/gene therapy use)
  • Vector must have: origin of replication, selectable marker (antibiotic resistance), multiple cloning site
4. Ligation
  • DNA ligase joins the foreign DNA fragment (insert) with the cut vector, forming recombinant DNA
5. Transformation/Transfection
  • Recombinant DNA introduced into host cell (bacteria — E. coli; or eukaryotic cells) via:
    • Heat shock/CaCl₂ method
    • Electroporation
    • Microinjection
    • Gene gun (biolistic method)
    • Viral vector-mediated transfer
6. Selection of transformants
  • Using antibiotic resistance markers or blue-white screening (lacZ system)
7. Screening for the gene of interest
  • Colony hybridization, PCR-based screening
8. Expression/Cloning
  • Amplification of the gene, or expression of protein product

Polymerase Chain Reaction (PCR) — important allied technique

  • In vitro amplification of DNA using:
    • Template DNA
    • Primers (forward/reverse)
    • Taq DNA polymerase (thermostable)
    • dNTPs
  • Steps: Denaturation (94-96°C) → Annealing (50-65°C) → Extension (72°C) — repeated cycles (exponential amplification)
Diagram to draw: Complete rDNA technology flowchart — isolate gene → cut with restriction enzyme → cut vector with same enzyme → ligate with DNA ligase → transform into host bacterium → select on antibiotic plate → clone/express.

Applications of Recombinant DNA Technology

A. Medical:
  • Recombinant insulin (Humulin) — first rDNA product, produced in E. coli
  • Human growth hormone (Somatotropin) for dwarfism
  • Hepatitis B vaccine — recombinant surface antigen
  • Factor VIII/IX for hemophilia
  • Erythropoietin for anemia
  • Monoclonal antibodies (trastuzumab, rituximab)
  • Gene therapy vectors
  • Diagnostic tools: DNA probes, PCR-based diagnosis (e.g., HIV, TB, COVID-19 RT-PCR)
B. Agricultural:
  • Bt cotton/Bt brinjal (pest resistance via Cry genes from Bacillus thuringiensis)
  • Golden rice (Vitamin A enriched, beta-carotene pathway genes)
  • Herbicide-resistant crops (Roundup Ready soybean)
  • Flavr Savr tomato (delayed ripening)
C. Industrial:
  • Enzyme production (proteases, amylases for detergents)
  • Biofuel production
D. Forensic:
  • DNA fingerprinting (RFLP, STR analysis) for paternity testing, criminal identification
E. Research:
  • Gene knockout/knock-in studies
  • Transgenic animal models (e.g., transgenic mice)
  • CRISPR-Cas9 genome editing (modern extension of rDNA technology)

3. Gene Therapy and RNA Processing

A. Gene Therapy

Definition: Introduction, removal, or alteration of genetic material within a patient's cells to treat a disease.
Types:
1. Based on target cell:
  • Germline gene therapy — modifies germ cells (sperm/egg); changes heritable; ethically controversial, not used clinically in humans
  • Somatic gene therapy — modifies somatic cells; not heritable; clinically approved approach
2. Based on method:
  • Ex vivo gene therapy: Cells removed from patient → gene inserted in vitro → modified cells reintroduced
    • Example: ADA-SCID (Adenosine Deaminase deficiency - Severe Combined Immunodeficiency) — first successful gene therapy (1990, by W. French Anderson): lymphocytes withdrawn, functional ADA gene introduced via retroviral vector, reinfused
  • In vivo gene therapy: Vector carrying therapeutic gene directly administered into patient's body
    • Example: Luxturna (RPE65 gene, for inherited retinal dystrophy), Zolgensma (SMN1 gene for spinal muscular atrophy)
Vectors used in gene therapy:
VectorFeature
RetrovirusIntegrates into host genome; used for dividing cells
AdenovirusNon-integrating, strong immune response
Adeno-associated virus (AAV)Low immunogenicity, widely used now
LentivirusCan infect non-dividing cells
Liposomes/Naked DNANon-viral, safer but less efficient
Approaches:
  • Gene augmentation (adding a normal copy of gene)
  • Gene silencing (using antisense/siRNA to block defective gene)
  • Gene editing (CRISPR-Cas9, to correct the mutation directly)
  • Oncolytic virus therapy (for cancers)
Diagram to draw: Ex vivo vs in vivo gene therapy comparison chart with retroviral vector transducing target cell.
Challenges: Immune response, insertional mutagenesis (risk of oncogene activation, as seen in some X-SCID trials), transient expression, high cost, delivery efficiency.

B. RNA Processing (Post-transcriptional modification of pre-mRNA)

Occurs in the nucleus after transcription by RNA Pol II, converting primary transcript (pre-mRNA/hnRNA) into mature mRNA.
Three major steps:
1. 5' Capping
  • Addition of 7-methylguanosine cap to the 5' end
  • Function: Protects mRNA from degradation (5'→3' exonucleases), assists ribosome binding for translation initiation
2. Splicing
  • Removal of introns (non-coding intervening sequences) and joining of exons (coding sequences)
  • Carried out by the spliceosome — a complex of snRNPs (U1, U2, U4, U5, U6 small nuclear RNAs + proteins)
  • Mechanism: recognizes GU (5' splice site) and AG (3' splice site) consensus sequences, forms a lariat structure, cuts and ligates exons
  • Alternative splicing: different combinations of exons joined → multiple protein isoforms from a single gene (major source of proteome diversity)
3. 3' Polyadenylation
  • Cleavage downstream of AAUAAA signal sequence
  • Addition of ~200 adenine residues (poly-A tail) by poly-A polymerase
  • Function: mRNA stability, export from nucleus, translation efficiency
Other RNA processing events:
  • RNA editing — post-transcriptional alteration of RNA sequence (e.g., ApoB mRNA editing, ADAR enzymes converting A→I)
  • RNA interference (RNAi) — siRNA/miRNA-mediated silencing of gene expression
Diagram to draw: Pre-mRNA with exons/introns → capping at 5' end → spliceosome removing introns (lariat intermediate) → poly-A tail addition at 3' end → mature mRNA exiting nuclear pore.

4. MAPK Signalling Pathway in Eukaryotic Cells

MAPK (Mitogen-Activated Protein Kinase) pathway is a conserved three-tiered kinase cascade that transduces extracellular signals (growth factors, cytokines, stress) into intracellular responses (proliferation, differentiation, apoptosis).

General Architecture (three-tier kinase cascade):

Extracellular signal (growth factor)
        ↓
Receptor (RTK) activation
        ↓
MAPKKK (MAP kinase kinase kinase) — e.g., Raf
        ↓ (phosphorylates)
MAPKK (MAP kinase kinase) — e.g., MEK
        ↓ (phosphorylates on Thr and Tyr)
MAPK (MAP kinase) — e.g., ERK
        ↓
Nuclear translocation → Transcription factor activation → Gene expression

Major MAPK sub-families:

PathwayActivated byKey kinasesMain outcome
ERK1/2 (classical)Growth factors (EGF, PDGF) via RTK-RasRaf → MEK1/2 → ERK1/2Cell proliferation, differentiation
JNK (SAPK)Stress, UV, cytokines (TNF, IL-1)MEKK → MKK4/7 → JNKApoptosis, inflammation
p38 MAPKOsmotic stress, inflammatory cytokinesMEKK → MKK3/6 → p38Inflammation, apoptosis, stress response

Mechanism of activation (ERK pathway as prototype):

  1. Growth factor binds Receptor Tyrosine Kinase (RTK) → receptor dimerization and autophosphorylation
  2. Adaptor protein Grb2 binds phosphotyrosine residues
  3. Grb2 recruits SOS (guanine nucleotide exchange factor)
  4. SOS activates Ras (GDP → GTP exchange)
  5. Ras-GTP activates Raf (MAPKKK)
  6. Raf phosphorylates and activates MEK (MAPKK)
  7. MEK phosphorylates ERK (MAPK) on both threonine and tyrosine residues
  8. Activated ERK translocates to nucleus, phosphorylates transcription factors (Elk-1, c-Fos, c-Myc)
  9. Gene transcription → cell cycle progression, proliferation
Termination/Regulation: MAPK phosphatases (MKPs/DUSPs) dephosphorylate and inactivate MAPKs; negative feedback loops.
Clinical relevance:
  • Mutated Ras (oncogene, e.g., KRAS in pancreatic/colorectal cancer) or BRAF (V600E mutation in melanoma) causes constitutive MAPK activation → uncontrolled proliferation → cancer
  • Targeted drugs: Vemurafenib (BRAF inhibitor), Trametinib (MEK inhibitor)
Diagram to draw: Three-tiered cascade box diagram: RTK at membrane → Grb2-SOS → Ras → Raf (MAPKKK) → MEK (MAPKK) → ERK (MAPK) → nucleus with transcription factor activation, showing branching into ERK/JNK/p38 arms.

5. Protein Synthesis (Translation) — Detailed

Protein synthesis has two major phases: Transcription (DNA→mRNA, covered above) and Translation (mRNA→protein). Here is translation in detail as typically asked:

Requirements:

  • mRNA (template)
  • Ribosomes (70S in prokaryotes: 30S+50S; 80S in eukaryotes: 40S+60S)
  • tRNA (adaptor molecules, charged with amino acids)
  • Aminoacyl-tRNA synthetases (charge tRNA with correct amino acid — ATP dependent)
  • Initiation, elongation, release factors
  • GTP, Mg²⁺

Steps of Translation:

1. Activation of amino acid
  • Amino acid + ATP + tRNA → aminoacyl-tRNA (charged tRNA) + AMP + PPi (catalyzed by aminoacyl-tRNA synthetase — high specificity/proofreading step)
2. Initiation
  • Small ribosomal subunit binds mRNA at 5' cap (eukaryotes) or Shine-Dalgarno sequence (prokaryotes)
  • Initiator tRNA (Met-tRNA in eukaryotes, fMet-tRNA in prokaryotes) pairs with start codon (AUG)
  • Initiation factors (eIFs in eukaryotes, IFs in prokaryotes) mediate assembly
  • Large ribosomal subunit joins → forms complete initiation complex with initiator tRNA in P site
3. Elongation (cyclical, repeated for each codon)
  • Codon recognition: Aminoacyl-tRNA (matching next codon) enters A site, assisted by elongation factor (EF-Tu/eEF1, GTP-dependent)
  • Peptide bond formation: Peptidyl transferase (a ribozyme activity of large rRNA) catalyzes bond between amino acid in A site and growing peptide chain in P site
  • Translocation: Ribosome moves one codon (3 nucleotides) along mRNA (5'→3'), catalyzed by EF-G/eEF2 (GTP-dependent); tRNA shifts from A→P→E sites, empty tRNA exits from E site
4. Termination
  • Stop codon (UAA, UAG, UGA) enters A site — no corresponding tRNA
  • Release factors (RF1/RF2/RF3 in prokaryotes; eRF1/eRF3 in eukaryotes) bind
  • Peptidyl transferase hydrolyzes bond between polypeptide and tRNA → releases polypeptide
  • Ribosomal subunits dissociate
5. Post-translational modifications
  • Folding (chaperones — Hsp70, chaperonins)
  • Cleavage of signal peptides
  • Glycosylation, phosphorylation, disulfide bond formation, ubiquitination
  • Targeting to organelles (via signal sequences, e.g., ER, mitochondria, nucleus)

Key features to mention for marks:

  • Genetic code is triplet, degenerate, non-overlapping, nearly universal, unambiguous
  • Polysome/Polyribosome: multiple ribosomes translating same mRNA simultaneously — increases efficiency
  • Wobble hypothesis: explains degeneracy — third codon base pairing is flexible
Diagram to draw: Ribosome with A, P, E sites labeled, mRNA threading through, tRNA entering A site with amino acid, peptide bond formation, and translocation arrow — label small/large subunits, growing polypeptide chain.

6. Ras-MAP Kinase Pathway and Signal Transduction through Ion Channels

A. Ras-MAP Kinase Pathway (detailed mechanism — expands on Topic 4)

Ras is a small monomeric G-protein (21 kDa) that acts as a molecular switch, cycling between inactive (Ras-GDP) and active (Ras-GTP) states.
Step-by-step signal transduction:
  1. Ligand binding: Growth factor (e.g., EGF) binds extracellular domain of Receptor Tyrosine Kinase (RTK)
  2. Receptor dimerization and trans-autophosphorylation of intracellular tyrosine residues
  3. Adaptor recruitment: Grb2 (via SH2 domain) binds phosphotyrosines
  4. GEF recruitment: Grb2 (via SH3 domain) recruits SOS (Son of Sevenless — a Guanine nucleotide Exchange Factor)
  5. Ras activation: SOS catalyzes exchange of GDP for GTP on Ras → Ras-GTP (active form)
  6. Ras-GTP activates Raf (serine/threonine kinase, MAPKKK) by recruiting it to the membrane
  7. Raf phosphorylates MEK (MAPKK)
  8. MEK phosphorylates ERK (MAPK) on Thr and Tyr residues (dual phosphorylation)
  9. ERK dimerizes, translocates to nucleus
  10. Phosphorylates transcription factors (Elk-1, c-Fos, c-Jun, c-Myc) → activates immediate early genes → cell proliferation, differentiation, survival
Inactivation: GAP (GTPase Activating Protein) enhances intrinsic GTPase activity of Ras → hydrolyzes GTP to GDP → Ras returns to inactive state (negative regulation)
Clinical significance:
  • Oncogenic RAS mutations (point mutations at codons 12, 13, 61) impair GAP-mediated GTP hydrolysis → Ras locked in active GTP-bound state → constitutive proliferative signaling → found in ~30% of human cancers (pancreatic, colorectal, lung)
  • This pathway is a major target for anticancer drug development
Diagram to draw: Membrane receptor → Grb2-SOS complex → Ras (GDP↔GTP cycle with GEF/GAP) → Raf → MEK → ERK → nucleus, with a side inset showing normal GTPase cycle vs oncogenic Ras stuck in GTP-bound state.

B. Signal Transduction through Ion Channels

Ion channel-linked receptors (ionotropic receptors) provide the fastest mode of signal transduction (milliseconds), primarily in excitable tissue (neurons, muscle).
Types of ion channels involved in signalling:
1. Ligand-gated ion channels (Ionotropic receptors)
  • Channel opens directly upon neurotransmitter binding (no second messenger needed)
  • Examples:
    • Nicotinic acetylcholine receptor — cation channel (Na⁺/K⁺), opens on ACh binding → depolarization → muscle contraction
    • GABA-A receptor — Cl⁻ channel, opens on GABA binding → hyperpolarization → inhibitory neurotransmission
    • Glutamate receptors (NMDA, AMPA) — cation channels, excitatory transmission
2. Voltage-gated ion channels
  • Open/close in response to changes in membrane potential
  • Examples: Voltage-gated Na⁺ channels (action potential generation/upstroke), voltage-gated K⁺ channels (repolarization), voltage-gated Ca²⁺ channels (neurotransmitter release, muscle contraction, second messenger generation)
3. Second messenger-gated (G-protein coupled) ion channels
  • Indirect gating: GPCR activation → G-protein → second messenger (cAMP, IP3, DAG) → modulates channel
  • Example: cGMP-gated channels in retinal rod cells (phototransduction); cardiac muscarinic K⁺ channels via Gβγ subunits
Mechanism (example — Nicotinic ACh receptor at neuromuscular junction):
  1. Action potential reaches presynaptic terminal
  2. Voltage-gated Ca²⁺ channels open → Ca²⁺ influx
  3. Ca²⁺ triggers synaptic vesicle fusion → ACh release into synaptic cleft
  4. ACh binds nicotinic receptor (ligand-gated Na⁺/K⁺ channel) on postsynaptic membrane
  5. Conformational change opens channel → Na⁺ influx (net) → depolarization (End Plate Potential)
  6. If threshold reached → voltage-gated Na⁺ channels open → action potential propagates → muscle contraction
Key features distinguishing ion channel signalling from other pathways:
  • Extremely rapid response (milliseconds vs seconds-minutes for GPCR/RTK pathways)
  • Directly converts chemical signal into electrical signal
  • No amplification via enzymatic cascade (unlike GPCR/second messenger systems) — a direct structural change
Diagram to draw: Neuromuscular junction — presynaptic terminal with voltage-gated Ca²⁺ channels, synaptic vesicles releasing ACh, postsynaptic membrane with nicotinic ligand-gated Na⁺/K⁺ channel opening, and ion flow arrows.

Exam tip summary

For each of these LAQs, structure your answer as: Definition → Classification/Types → Mechanism (stepwise, use flowcharts) → Labelled diagram → Clinical/biotechnological significance → Conclusion. This structure consistently scores full marks because examiners look for definition, mechanism with sequence, and application/relevance.

?

Searching Images

Lac operon gene regulation diagram repressor operator

Searching Images

types of gene mutations point mutation frameshift missense nonsense diagram

Searching Images

recombinant DNA technology cloning flowchart restriction enzyme vector plasmid

Searching Images

gene therapy ex vivo in vivo viral vector diagram

A medical infographic illustrating three clinical applications of adenoviral (Ad) vectors: vaccine development, oncolytic therapy, and gene therapy. The diagram starts on the left with the upstream process of 'Vector production in permissive cells' using an 'Adenoviral plasmid'. The top panel, 'VECTOR VACCINE', shows a modified Ad carrying DNA for an immunogenic protein being injected into a patient, leading to intracellular synthesis of the protein and subsequent systemic antibody production. The middle panel, 'ONCOLYTIC VECTOR', demonstrates a targeted approach: in healthy cells, viral replication is blocked, while in tumor cells, the vector triggers cancer-specific replication leading to cell lysis. The bottom panel, 'GENE THERAPY', illustrates an ex vivo process where stem cells are harvested from a patient, modified with a therapeutic transgene using an adenoviral vector, and then readministered. The diagram uses standard symbols for DNA plasmids, viral capsids, and cellular structures to explain molecular biotechnology and immunotherapy concepts.

A medical infographic illustrating three clinical applications of adenoviral (Ad) vectors: vaccine development, oncolytic therapy, and gene therapy. The diagram starts on the left with the upstream process of 'Vector production in permissive cells' using an 'Adenoviral plasmid'. The top panel, 'VECTOR VACCINE', shows a modified Ad carrying DNA for an immunogenic protein being injected into a patient, leading to intracellular synthesis of the protein and subsequent systemic antibody production. The middle panel, 'ONCOLYTIC VECTOR', demonstrates a targeted approach: in healthy cells, viral replication is blocked, while in tumor cells, the vector triggers cancer-specific replication leading to cell lysis. The bottom panel, 'GENE THERAPY', illustrates an ex vivo process where stem cells are harvested from a patient, modified with a therapeutic transgene using an adenoviral vector, and then readministered. The diagram uses standard symbols for DNA plasmids, viral capsids, and cellular structures to explain molecular biotechnology and immunotherapy concepts.

This composite educational image illustrates the use of in vivo bioluminescence imaging (IVIS) to study lentiviral vector transduction efficiency in mice. Section A shows a genetic diagram of the plenti.GFP-NLuc lentiviral vector and the experimental workflow involving intraperitoneal (i.p.) injection into wild-type and SAMHD1-knockout (KO) mice. Section B presents pseudocolored luciferase signal maps comparing wild-type and KO mice at days 1, 3, and 7. The KO mice demonstrate significantly higher luminescence intensity (p≤0.0001), particularly in the abdominal region, indicating that SAMHD1 restricts lentiviral transduction in vivo. Section C compares the durability of luciferase expression between ex vivo transduced dendritic cells (BMDCs) and direct lentivirus injection. Sequential images and bar graphs show that direct lentiviral injection leads to more sustained, high-level expression (extending to day 51) localized primarily to the spleen, whereas transduced BMDCs show diminishing signal by day 21. This material demonstrates concepts in gene therapy, virology, and the role of host restriction factors in viral transduction.

This composite educational image illustrates the use of in vivo bioluminescence imaging (IVIS) to study lentiviral vector transduction efficiency in mice. Section A shows a genetic diagram of the plenti.GFP-NLuc lentiviral vector and the experimental workflow involving intraperitoneal (i.p.) injection into wild-type and SAMHD1-knockout (KO) mice. Section B presents pseudocolored luciferase signal maps comparing wild-type and KO mice at days 1, 3, and 7. The KO mice demonstrate significantly higher luminescence intensity (p≤0.0001), particularly in the abdominal region, indicating that SAMHD1 restricts lentiviral transduction in vivo. Section C compares the durability of luciferase expression between ex vivo transduced dendritic cells (BMDCs) and direct lentivirus injection. Sequential images and bar graphs show that direct lentiviral injection leads to more sustained, high-level expression (extending to day 51) localized primarily to the spleen, whereas transduced BMDCs show diminishing signal by day 21. This material demonstrates concepts in gene therapy, virology, and the role of host restriction factors in viral transduction.

Searching Images

mRNA splicing spliceosome pre-mRNA processing diagram exon intron

Searching Images

MAPK signaling pathway ERK cascade diagram Ras Raf MEK

A pathophysiology diagram illustrating the canonical MAPK/ERK signaling pathway and its exploitation by viral pathogens. The diagram shows the cell membrane with various receptors, including Receptor Tyrosine Kinases (RTK) and G-protein coupled receptors (GPCR), responding to growth factors, cytokines, chemokines, and viruses. The intracellular signaling cascade initiates with Grb2 and SOS facilitating the transition of RAS-GDP to RAS-GTP. The signal proceeds through a sequential phosphorylation relay of RAF, MEK, and ERK. Activated ERK translocates from the cytoplasm to the nucleus, where it activates transcription factors Fos and ELK to influence gene expression. The diagram highlights points of viral interference: SARS-CoV-2 entry via ACE2, influenza replication utilizing RSK1, and HIV replication involving Gag MA, all linked to downstream ERK components. Key pharmacological inhibitors for potential therapeutic repurposing are noted, including Vemurafenib/Dabrafenib (RAF), Trametinib/Cobimetinib (MEK), and ONC201/Ulixertinib (ERK), alongside RAS inhibitors like ARS-853.

A pathophysiology diagram illustrating the canonical MAPK/ERK signaling pathway and its exploitation by viral pathogens. The diagram shows the cell membrane with various receptors, including Receptor Tyrosine Kinases (RTK) and G-protein coupled receptors (GPCR), responding to growth factors, cytokines, chemokines, and viruses. The intracellular signaling cascade initiates with Grb2 and SOS facilitating the transition of RAS-GDP to RAS-GTP. The signal proceeds through a sequential phosphorylation relay of RAF, MEK, and ERK. Activated ERK translocates from the cytoplasm to the nucleus, where it activates transcription factors Fos and ELK to influence gene expression. The diagram highlights points of viral interference: SARS-CoV-2 entry via ACE2, influenza replication utilizing RSK1, and HIV replication involving Gag MA, all linked to downstream ERK components. Key pharmacological inhibitors for potential therapeutic repurposing are noted, including Vemurafenib/Dabrafenib (RAF), Trametinib/Cobimetinib (MEK), and ONC201/Ulixertinib (ERK), alongside RAS inhibitors like ARS-853.

This pathophysiology diagram illustrates the complex signaling network involving SOX2 in bladder cancer cells, highlighting its role in tumor proliferation and chemoresistance. The diagram is divided into four main regulatory pathways: (A) The MAPK/ERK pathway, showing the RAS-RAF-MEK-ERK cascade where active RAS-GTP leads to ERK phosphorylation (pERK) and subsequent SOX2 activation, regulated by RASAL2. (B) The MAPK/JNK pathway, where ChlA-F triggers JNK and c-Jun phosphorylation, modulating SOX2 via miR-200c. (C) The SOX2-IGF2-AKT axis, demonstrating a positive feedback loop where SOX2 promotes IGF2 expression (inhibiting IGFBP1), which then activates AKT via phosphorylation (pAKT). (D) The COX2/PGE2 and YAP1 pathways, showing YAP1 directly activating SOX2 and COX2, while the COX2-PGE2 axis inhibits let-7, a microRNA that typically represses SOX2. Centrally, SOX2 acts as a master transcription factor that drives the transformation of bladder cancer cells into phenotypes characterized by rapid proliferation and enhanced chemoresistance.

This pathophysiology diagram illustrates the complex signaling network involving SOX2 in bladder cancer cells, highlighting its role in tumor proliferation and chemoresistance. The diagram is divided into four main regulatory pathways: (A) The MAPK/ERK pathway, showing the RAS-RAF-MEK-ERK cascade where active RAS-GTP leads to ERK phosphorylation (pERK) and subsequent SOX2 activation, regulated by RASAL2. (B) The MAPK/JNK pathway, where ChlA-F triggers JNK and c-Jun phosphorylation, modulating SOX2 via miR-200c. (C) The SOX2-IGF2-AKT axis, demonstrating a positive feedback loop where SOX2 promotes IGF2 expression (inhibiting IGFBP1), which then activates AKT via phosphorylation (pAKT). (D) The COX2/PGE2 and YAP1 pathways, showing YAP1 directly activating SOX2 and COX2, while the COX2-PGE2 axis inhibits let-7, a microRNA that typically represses SOX2. Centrally, SOX2 acts as a master transcription factor that drives the transformation of bladder cancer cells into phenotypes characterized by rapid proliferation and enhanced chemoresistance.

A pathophysiology diagram illustrating the ErbB/HER2 signaling network, organized into three functional sections: input, signal processing, and output. (a) The input part shows extracellular ligands binding to transmembrane ErbB receptors (EGFR, HER2, HER3, and HER4), highlighting the role of HER2 heterodimers. (b) The signal processing part depicts three vertical intracellular signaling cascades: the PI3K/AKT/mTOR pathway (green), the JAK/STAT3 pathway (blue), and the RAS/RAF/MEK/ERK (MAPK) pathway (yellow). Each cascade follows a downward flow of activation. (c) The output part shows these pathways converging on the cell nucleus, represented by a DNA double helix. This section indicates downstream cellular effects including cell division, migration, differentiation, and apoptosis. This schematic provides a clinical overview of how HER2 overexpression drives tumorigenic processes and drug resistance mechanisms in cancers such as invasive breast cancer.

A pathophysiology diagram illustrating the ErbB/HER2 signaling network, organized into three functional sections: input, signal processing, and output. (a) The input part shows extracellular ligands binding to transmembrane ErbB receptors (EGFR, HER2, HER3, and HER4), highlighting the role of HER2 heterodimers. (b) The signal processing part depicts three vertical intracellular signaling cascades: the PI3K/AKT/mTOR pathway (green), the JAK/STAT3 pathway (blue), and the RAS/RAF/MEK/ERK (MAPK) pathway (yellow). Each cascade follows a downward flow of activation. (c) The output part shows these pathways converging on the cell nucleus, represented by a DNA double helix. This section indicates downstream cellular effects including cell division, migration, differentiation, and apoptosis. This schematic provides a clinical overview of how HER2 overexpression drives tumorigenic processes and drug resistance mechanisms in cancers such as invasive breast cancer.

Searching Images

protein synthesis translation ribosome mRNA tRNA diagram A site P site

Educational pathophysiology diagram illustrating the mechanisms of action for four classes of protein synthesis inhibitors acting on the bacterial ribosome. The diagram is divided into four numbered quadrants: (1) Tetracyclines, represented by red linked circles, are shown binding to the 30S small subunit, which physically blocks aminoacyl-tRNA from binding to the A-site, thereby inhibiting translation. (2) Aminoglycosides, depicted as green bars, demonstrate three distinct mechanisms: (A) blocking the initiation of protein synthesis, (B) inhibiting tRNA translocation from the A-site to the P-site, and (C) causing mRNA misreading, leading to the incorporation of incorrect amino acids. (3) Macrolides, Lincosamides, and Type B Streptogramins are shown blocking the polypeptide exit tunnel of the 50S large subunit, preventing the extension of the growing peptide chain. (4) Oxazolidinones, shown as purple circles, bind to the 50S subunit at the peptidyl transferase center, inhibiting the formation of the 70S initiation complex and blocking early translation steps. Each panel illustrates key components including the 50S and 30S subunits, mRNA, tRNA, and the growing peptide chain.

Educational pathophysiology diagram illustrating the mechanisms of action for four classes of protein synthesis inhibitors acting on the bacterial ribosome. The diagram is divided into four numbered quadrants: (1) Tetracyclines, represented by red linked circles, are shown binding to the 30S small subunit, which physically blocks aminoacyl-tRNA from binding to the A-site, thereby inhibiting translation. (2) Aminoglycosides, depicted as green bars, demonstrate three distinct mechanisms: (A) blocking the initiation of protein synthesis, (B) inhibiting tRNA translocation from the A-site to the P-site, and (C) causing mRNA misreading, leading to the incorporation of incorrect amino acids. (3) Macrolides, Lincosamides, and Type B Streptogramins are shown blocking the polypeptide exit tunnel of the 50S large subunit, preventing the extension of the growing peptide chain. (4) Oxazolidinones, shown as purple circles, bind to the 50S subunit at the peptidyl transferase center, inhibiting the formation of the 70S initiation complex and blocking early translation steps. Each panel illustrates key components including the 50S and 30S subunits, mRNA, tRNA, and the growing peptide chain.

Searching Images

ion channel signal transduction neuromuscular junction acetylcholine receptor diagram

Searching Images

DNA cloning vector plasmid bacteria genetic engineering

Searching Images

sickle cell anemia hemoglobin mutation diagram

I found some diagrams from the medical image library and will fold them into the answers. Search coverage for a few classic textbook schematics (lac operon, mutation types chart, RFLP/cloning flowchart, spliceosome, ion channel/NMJ) came up empty in this database, so for those I'll keep the labelled hand-drawing guidance from before.

Diagrams Retrieved

Gene Therapy (ex vivo/in vivo, viral vector-mediated) — relevant to Topic 3:
Adenoviral vector gene therapy diagram
This shows the bottom panel especially: stem cells harvested from patient → modified ex vivo with adenoviral vector carrying therapeutic transgene → readministered to patient. Top/middle panels show related vaccine and oncolytic vector applications, useful as a comparison point in your answer.
MAPK/ERK and Ras-Raf-MEK-ERK cascade — relevant to Topics 4 and 6:
MAPK ERK signaling pathway with RAS-RAF-MEK-ERK cascade
This is an excellent exam diagram: shows RTK/GPCR at the membrane, Grb2-SOS converting RAS-GDP to RAS-GTP, the RAF→MEK→ERK relay, nuclear translocation activating Fos/Elk transcription factors, and even labels the clinically relevant inhibitor drugs (Vemurafenib/Dabrafenib block RAF, Trametinib/Cobimetinib block MEK) — good for a "clinical correlation" line in your LAQ.
Ribosome structure during translation (A-site/P-site/50S/30S) — relevant to Topic 5:
Ribosome structure showing 30S and 50S subunits, mRNA, tRNA and peptide chain
This diagram was originally built to show antibiotic mechanisms, but it clearly labels the 30S/50S subunits, mRNA, tRNA, and the A-site/P-site/peptide exit tunnel — you can redraw just the ribosome/mRNA/tRNA/peptide labels for your protein synthesis diagram and ignore the drug annotations, or optionally mention it as a bonus note: "clinically, several antibiotics exploit this same ribosomal machinery (tetracyclines block A-site binding, aminoglycosides cause misreading, macrolides block the exit tunnel)."

Diagrams not found in the image library — draw these by hand as described

For a full topper-style answer sheet, sketch these simple labelled diagrams (as I described in the previous message) since the database didn't return matches:
  1. Lac operon on/off switch — repressor bound to operator (off) vs allolactose-repressor complex releasing operator with RNA polymerase transcribing (on)
  2. Types of point mutations — a normal DNA/mRNA/protein strand compared side-by-side with silent, missense, nonsense, and frameshift versions
  3. Recombinant DNA technology flowchart — gene isolation → restriction digestion → ligation into vector → transformation into host → selection → cloning/expression
  4. Pre-mRNA splicing — exons/introns → spliceosome (snRNPs) forming lariat → mature spliced mRNA with cap and poly-A tail
  5. Neuromuscular junction ion channel signalling — voltage-gated Ca²⁺ channel at presynaptic terminal → ACh vesicle release → nicotinic ligand-gated Na⁺/K⁺ channel opening on postsynaptic membrane → depolarization
These five are simple box-and-arrow or circle diagrams that are fast to reproduce in an exam and score full diagram marks even without a printed reference — examiners mainly check for correct labels and sequence, not artistic accuracy.
If you want, tell me which single topic you want to now expand into a full page-length written-out answer (with the flowing paragraph text an examiner expects, not just bullet points), and I'll write that one out completely.
This is a shared conversation. Sign in to Orris to start your own chat.